Teresa Bernal

7.0k total citations · 1 hit paper
73 papers, 2.8k citations indexed

About

Teresa Bernal is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Teresa Bernal has authored 73 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 23 papers in Public Health, Environmental and Occupational Health and 19 papers in Oncology. Recurrent topics in Teresa Bernal's work include Acute Myeloid Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (20 papers) and Lymphoma Diagnosis and Treatment (9 papers). Teresa Bernal is often cited by papers focused on Acute Myeloid Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (20 papers) and Lymphoma Diagnosis and Treatment (9 papers). Teresa Bernal collaborates with scholars based in Spain, United States and Italy. Teresa Bernal's co-authors include Donald J. D’Amico, Kiang-Teck J Yeo, Tet-Kin Yeo, A.P. Adamis, Joan W. Miller, J Folkman, Josep‐María Ribera, Carlos López-Otı́n, Mar Tormo and Francisco Rodríguez and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Teresa Bernal

69 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy

1994 1.0k citations Teresa Bernal et al. profile →

Peers

Countries citing papers authored by Teresa Bernal

Since Specialization

Citations

This map shows the geographic impact of Teresa Bernal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teresa Bernal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teresa Bernal more than expected).

Fields of papers citing papers by Teresa Bernal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teresa Bernal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teresa Bernal. The network helps show where Teresa Bernal may publish in the future.

Co-authorship network of co-authors of Teresa Bernal

This figure shows the co-authorship network connecting the top 25 collaborators of Teresa Bernal. A scholar is included among the top collaborators of Teresa Bernal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teresa Bernal. Teresa Bernal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia 2024 ·Scientific Reports ·(unknown), (unknown), M. Rosario Rodicio, Javier Fernández, Teresa Bernal, (unknown), (unknown), (unknown), Abelardo Margollés, Carlos Sabater	2
2	Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study 2024 ·British Journal of Haematology ·Klaus Geißler, Zdeněk Kořı́stek, Teresa Bernal, Jan Novák, Gabriela Rodríguez‐Macías, Stephan Metzelder, Árpád Illés, Jiřı́ Mayer, Montserrat Arnán, Mary‐Margaret Keating, (unknown), Monia Lunghi, Nicola Stefano Fracchiolla, Uwe Platzbecker, Valeria Santini, Yuri Sano, Aram Oganesian, Harold Keer, Michael Lübbert	8
3	Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes 2024 ·Therapeutic Advances in Hematology ·(unknown), Julio Dávila, Maria López‐Pavía, Esperanza Such, Teresa Bernal, Fernando Ramos, Marisa Calabuig, Jesús María Hernández-Sánchez, Helena Pomares, Mercedes Sánchez‐Barba, María Abáigar, Bernardo González, (unknown), Reyes Sancho-Tello, (unknown), (unknown), Carlos Cerveró, Guillermo Sanz, Jesús María Hernández‐Rivas, María Díez‐Campelo	3
4	Pivotal role of BCL11B in the immune, hematopoietic and nervous systems: a review of the BCL11B-associated phenotypes from the genetic perspective 2024 ·Genes and Immunity ·José María García-Aznar, Sara Álvarez, Teresa Bernal	5
5	FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety 2023 ·Trials ·(unknown), (unknown), (unknown), Laura Solán, (unknown), (unknown), (unknown), (unknown), (unknown), Blanca Boluda, (unknown), (unknown), María Luz Amigo, (unknown), (unknown), (unknown), Javier Fernández, Teresa Bernal	1
6	Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice 2023 ·Journal of Personalized Medicine ·Fernando Ramos, (unknown), (unknown), Pilar Martı́nez, (unknown), Manuel Barrios, (unknown), Teresa Bernal, (unknown), (unknown), (unknown), Teresa Caballero‐Velázquez, Bernardo González, Albert Altés, (unknown), Pascual Fernández, María Antonia Durán, Rocío López, Montserrat Rafel, Josefina Serrano	1
7	Evaluation of a Shotgun Metagenomics Approach for Detection of ESBL- and/or Carbapenemase-Producing Enterobacterales in Culture Negative Patients Recovered from Acute Leukemia 2023 ·Microorganisms ·(unknown), Carlos Sabater, (unknown), (unknown), (unknown), Abelardo Margollés, M. Rosario Rodicio, Teresa Bernal, Javier Fernández	2
8	Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy ^* 2022 ·Leukemia & lymphoma ·Toshihiro Miyamoto, David Sanford, Ciprian Tomuleasa, Hui‐Hua Hsiao, (unknown), Anoop Enjeti, (unknown), Teresa Bernal, (unknown), Maria Paola Martelli, Birol Güvenç, (unknown), Yinghui Duan, (unknown), (unknown), Je‐Hwan Lee	8
9	Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study 2022 ·European Journal Of Haematology ·Tomoki� Ito, David Sanford, Ciprian Tomuleasa, Hui‐Hua Hsiao, (unknown), Anoop Enjeti, (unknown), Teresa Bernal, (unknown), Maria Paola Martelli, Birol Güvenç, Cat N. Bui, Alex J. Delgado, Yinghui Duan, (unknown), (unknown), Je‐Hwan Lee	6
10	The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia 2019 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Javier Fernández, (unknown), (unknown), Concepción Nicolás, Laura Vilorio-Marqués, Teresa Bernal	7
11	Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism 2019 ·Haematologica ·Luca Mazzarella, Edoardo Botteri, Anthony Matthews, Elena Gatti, (unknown), Vincenzo Bagnardi, Massimo Breccia, Pau Montesinos, Teresa Bernal, Cristina Gil, Timothy J. Ley, Miguel Á. Sanz, Krishnan Bhaskaran, Francesco Lo‐Coco, Pier Giuseppe Pelicci	30
12	The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment 2017 ·Annals of Hematology ·(unknown), (unknown), Sara Alonso, Enrique Colado, Teresa Bernal	13
13	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial 2016 ·Biology of Blood and Marrow Transplantation ·Mónica Cabrero, Alejandro Martı́n, Javier Briones, Jorge Gayoso, Isidro Jarque, Javier López, Carlos Grande, Inmaculada Heras, Reyes Arranz, Teresa Bernal, (unknown), Oriana López‐Godino, Eulogio Conde, Dolores Caballero	9
14	Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy 2015 ·Leukemia & lymphoma ·(unknown), David Gallardo, José González‐Campos, Jesús María Hernández‐Rivas, Pau Montesinos, Josep Sarrà, Cristina Gil, Pere Barba, Ramón Guàrdia, Salut Brunet, Teresa Bernal, (unknown), Eugènia Abella, (unknown), (unknown), Antònia Cladera, Jorge Gayoso, María Calbacho, Josep‐María Ribera, (unknown)	11
15	Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry 2015 ·Leukemia ·Teresa Bernal, Pablo Martínez‐Camblor, Joaquín Sánchez‐García, R. de Paz, Elisa Luño, Benet Nomdedeu, (unknown), Carmen Pedro, Mari Luz Amigo, Blanca Xicoy, Consuelo del Cañizo, Mar Tormo, (unknown), David Valcárcel, Salut Brunet, Luis Benlloch, Guillermo Sanz	67
16	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial 2014 ·Haematologica ·Javier Briones, Silvana Novelli, José A. García‐Marco, José Francisco Tomás, Teresa Bernal, Carlos Grande, Miguel Canales, António Torres, (unknown), Carlos Panizo, Isidro Jarque, (unknown), Matthew C. Hernandez, Eva González‐Barca, (unknown), D. Caballero, (unknown)	3
17	Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors 2012 ·Cancer Research ·Rocío G. Urdinguio, Agustín F. Fernández, Ángela Moncada-Pazos, Covadonga Huidobro, Ramón María Alvargonzález Rodríguez, Cecilia Ferrero, Pablo Martínez‐Camblor, Álvaro J. Obaya, Teresa Bernal, Adolfo Parra‐Blanco, Luı́s Rodrigo, Marı́a Santacana, Xavier Matías‐Guiu, Beatriz Soldevilla, Gemma Domínguez, Félix Bonilla, Santiago Cal, Carlos López-Otı́n, Mario F. Fraga	65
18	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome 2011 ·Leukemia Research ·(unknown), José Ramón González‐Porras, Esperanza Such, Benet Nomdedeu, Elisa Luño, R. de Paz, Félix Carbonell, Teresa Vallespı́, (unknown), Fernando Ramos, (unknown), Santiago Bonanad, Mercedes Sánchez‐Barba, Dolors Costa, Teresa Bernal, Guillermo Sanz, M.C. del Cañizo	17
19	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial 2009 ·Haematologica ·Josep‐María Ribera, Albert Oriol, Marcos González, María‐Belén Vídriales, S. Brunet, Jordi Esteve, Eloy del Potro, C Rivas, (unknown), Mar Tormo, (unknown), Josep Sarrà, Ricardo Parody, Jaime Pérez de Oteyza, E Bureo, Teresa Bernal, (unknown)	128
20	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) 2009 ·Annals of Hematology ·Carlos Santamaría, Carmen Chillón, Ramón García‐Sánz, Cristina Pérez, Marı́a Dolores Caballero, María‐Victoria Mateos, Fernando Ramos, Alfonso García de Coca, José María Alonso, Pilar Giraldo, Teresa Bernal, José Antonio Queizán, N. Rodríguez, Noemí Puig, Ana Balanzategui, María Eugenia Sarasquete, Miguel Alcoceba, Joaquı́n Dı́az-Mediavilla, Jesús F. San Miguel, Marcos González	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact